Teva Pharmaceutical Industries (TEVA) said Wednesday a phase 3 study of its fremanezumab drug to prevent episodic migraine in patients aged 6 to 17 years showed "statistically significant superior efficacy" compared with placebo.
The drug also showed a favorable safety profile "consistent with that observed in the adult population," the company said.
Teva said it continues to study the impact of fremanezumab on pediatric patients with chronic migraines and its long-term safety.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.